Treatment of hepatitis b virus cirrhosis

Hepatitis Monthly

Volumn 12, Issue 5, 2012, Pages 309-311

  Rizzetto, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatitis b virus; Liver cirrhosis; Therapeutics

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PLACEBO; TENOFOVIR;

EDITORIAL; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NEPHROTOXICITY; SURVIVAL; VIRUS REPLICATION;

EID: 84862618362     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6113     Document Type: Editorial

References (20)

1. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-242.
2. Das K, Datta S, Pal S, Hembram JR, Dhali GK, Santra A, et al. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010;30(7):1033-42.
3. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109(3):908-16.
4. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993;104(4):1116-21.
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-31.
6. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883-91.
7. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38(6):1419-27.
8. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplan tation patients with lamivudine-resistant hepatitis B: final longterm results. Liver Transpl. 2007;13(3):349-60.
9. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123(3):719-27.
10. Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Jr., Janssen HL, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103(11):2776-83.
11. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigenpositive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49(1):72-9.
12. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virusrelated decompensated cirrhosis. J Hepatol. 2010;52(2):176-82.
13. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54(1):91-100.
14. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50(6):2001-6.
15. Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71(18):2511-29.
16. Marzano A, Marengo A, Marietti M, Rizzetto M. Lactic acidosis during Entecavir treatment in decompensated hepatitis B virusrelated cirrhosis. Dig Liver Dis. 2011;43(12):1027-8.
17. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet- Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62-72.
18. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-93.
19. Marcellin P, Buti M, Gane EJ, Krastev Z, Flisiak R, Germanidis G, et al. Five years of treatment with TenofovirDF (TDF) for Chronic Hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. AASLD; 2011; Available from: http://www.multiwebcast.com/aasld/2011/thelivermeeting/13781/.
20. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348-56.